Showing 541-550 of 5061 results for "".
- First Participant Randomized in Dermaliq Therapeutic's Phase 1b/2 Trial Evaluating DLQ01 for AAhttps://practicaldermatology.com/news/first-participant-randomized-in-dermaliq-therapeutics-phase-1b2-trial-evaluating-dlq01-for-aa/2461470/The first participant has been randomized in a Phase 1b/2a trial of Dermaliq Therapeutics Inc.’s DLQ01 solution in men with androgenic alopecia. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ01 in men with and
- American Hair Research Society to Host Hybrid Alopecia Areata Summit 12/10-11https://practicaldermatology.com/news/american-hair-research-society-to-host-hybrid-alopecia-areata-summit-1210-11/2461459/The Alopecia Areata Summit “New Pathways, New Treatments” organized by the American Hair Research Society will be held December 10-11 at the New York Academy of Medicine, 1216 5th Ave., New York, NY. The meeting is being co-Chaired by Angela M. Christiano, PhD, Columbia Univ
- Beekman 1802 Gives Back: Brand Celebrates World Kindness Dayhttps://practicaldermatology.com/news/beekman-1802-gives-back-brand-celebrates-world-kindness-day/2461426/Beekman 1802 will celebrate World Kindness Day, an international holiday to promote kindness throughout the world. Root
- Cutera's AviClear Now Broadly Available to US Physicians and Practitionershttps://practicaldermatology.com/news/cuteras-aviclear-now-broadly-available-to-us-physicians-and-practitioners/2461416/Cutera, Inc.’s AviClear is now broadly available to physicians and practitioners treating patients throughout North America. AviClear is the first and only energy device to be both U.S. Food and Drug Administration cleared and Health Canada approved for
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month-1/2461411/November is Hyperhidrosis Awareness Month and the
- Octagam 10% Performs Well in Adults with Dermatomyositishttps://practicaldermatology.com/news/octagam-10-performs-well-in-adults-with-dermatomyositis/2461376/Octapharma’s Octagam 10% [Immune Globulin Intravenous (Human)] is efficacious and well-tolerated in adults with dermatomyositis, ac
- Midmark Gives Back: Trade-in Program Results in Nearly 1,000 Exam Tables Donated to World Visionhttps://practicaldermatology.com/news/midmark-gives-back-trade-in-program-results-in-nearly-1000-exam-tables-donated-to-world-vision/2461347/Midmark Corp.'s 2021 trade-in program collected 1,000 eligible exam tables. The tables were donated primarily to World Vision, where they are refurbished and delivered to clinics that provide health c
- Cutera: Aviclear Hits 1,000 Treatment Markhttps://practicaldermatology.com/news/cutera-aviclear-hits-1000-treatment-mark/2461333/More than 1,000 AviClear laser acne treatments have been performed in the United States, Cutera reports. AviClear is FDA-cleared for the treatment of mild, moderate and severe acne. Additionally, AviClear recently received approval from Health Canada for the treatment of all severities
- FDA Nod for Revelle Aesthetics, Inc's Avéli for Long-Term Reduction in Cellulitehttps://practicaldermatology.com/news/fda-nod-for-revelle-aesthetics-incs-aveli-for-long-term-reduction-in-cellulite/2461325/Revelle Aesthetics, Inc. scored an extended FDA clearance for Avéli. Avéli is now indicated for long-term reduction in the appearance of cellulite in the buttocks and thigh areas of adult females, demonstrating benefits through one year. "For far too l
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCChttps://practicaldermatology.com/news/sirnaomics-achieves-100-complete-response-in-phase-ii-clinical-trial-of-stp705-for-treatment-of-cutaneous-bcc/2461319/Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports. STP705 is a siRNA (small inte